Antibody-Drug Conjugates by Laurent DucryAntibody-Drug Conjugates by Laurent Ducry

Antibody-Drug Conjugates

EditorLaurent Ducry

Hardcover | August 3, 2013

Pricing and Purchase Info

$159.25 online 
$180.95 list price save 11%
Earn 796 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.  In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.  Written in the highly successful Methods in Molecular BiologyT format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Title:Antibody-Drug ConjugatesFormat:HardcoverDimensions:328 pages, 10 × 7.01 × 0 inPublished:August 3, 2013Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1627035400

ISBN - 13:9781627035408

Look for similar items by category:

Reviews

Table of Contents

1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review            Ingrid Sassoon and Véronique Blanc 2. Antibody-Drug Conjugate Target Selection: Critical Factors            Neil H. Bander 3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization            Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal 4. Antibody-Drug Conjugate Payloads            Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke 5. Linker Technologies for Antibody-Drug Conjugates            Birte Nolting 6. In Vivo Testing of Drug-Linker Stability            Pierre-Yves Abecassis and Céline Amara 7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates            Kedan Lin, Jay Tibbitts, and Ben-Quan Shen 8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment            Miriam I. Hensgen and Bernhard Stump 9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting            James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio 10. Protocols for Lysine Conjugation            Marie-Priscille Brun and Laurence Gauzy-Lazo 11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers            Sunil Bhakta, Helga Raab, and Jagath R. Junutula 12. Enzymatic Antibody Modification by Bacterial Transglutaminase            Patrick Dennler, Roger Schibli, and Eliane Fischer 13. Formulation Development of Antibody-Drug Conjugates            William J. Galush and Aditya A. Wakankar 14. Conjugation Process Development and Scale-Up            Bernhard Stump and Jessica Steinmann 15. Methods for Conjugating Antibodies to Nanocarriers            Anil Wagh and Benedict Law 16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy            Yan Chen 17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography            Jun Ouyang 18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS            Louisette Basa 19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF            Joyce Lin and Alexandru C. Lazar 20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)            Weibing Ding